4917. Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
The Inflation Reduction Act of 2022 authorizes Medicare to negotiate prices of top-selling drugs based on several factors, including therapeutic benefit compared with existing treatment options.
4918. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
作者: Jun Watanabe.;Kei Muro.;Kohei Shitara.;Kentaro Yamazaki.;Manabu Shiozawa.;Hisatsugu Ohori.;Atsuo Takashima.;Mitsuru Yokota.;Akitaka Makiyama.;Naoya Akazawa.;Hitoshi Ojima.;Yasuhiro Yuasa.;Keisuke Miwa.;Hirofumi Yasui.;Eiji Oki.;Takeo Sato.;Takeshi Naitoh.;Yoshito Komatsu.;Takeshi Kato.;Masamitsu Hihara.;Junpei Soeda.;Toshihiro Misumi.;Kouji Yamamoto.;Kiwamu Akagi.;Atsushi Ochiai.;Hiroyuki Uetake.;Katsuya Tsuchihara.;Takayuki Yoshino.
来源: JAMA. 2023年329卷15期1271-1282页
For patients with RAS wild-type metastatic colorectal cancer, adding anti-epidermal growth factor receptor (anti-EGFR) or anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibodies to first-line doublet chemotherapy is routine, but the optimal targeted therapy has not been defined.
4920. Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
作者: Nora B Henrikson.;Ilya Ivlev.;Paula R Blasi.;Matt B Nguyen.;Caitlyn A Senger.;Leslie A Perdue.;Jennifer S Lin.
来源: JAMA. 2023年329卷15期1296-1307页
Skin cancer is the most common cancer type and is a major cause of morbidity.
|